Department of Biochemistry and Molecular Biology, Center for Diabetes Research, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
J Biol Chem. 2010 Apr 23;285(17):12851-61. doi: 10.1074/jbc.M110.106534. Epub 2010 Feb 23.
Conversion to glycogen is a major fate of ingested glucose in the body. A rate-limiting enzyme in the synthesis of glycogen is glycogen synthase encoded by two genes, GYS1, expressed in muscle and other tissues, and GYS2, primarily expressed in liver (liver glycogen synthase). Defects in GYS2 cause the inherited monogenic disease glycogen storage disease 0. We have generated mice with a liver-specific disruption of the Gys2 gene (liver glycogen synthase knock-out (LGSKO) mice), using Lox-P/Cre technology. Conditional mice carrying floxed Gys2 were crossed with mice expressing Cre recombinase under the albumin promoter. The resulting LGSKO mice are viable, develop liver glycogen synthase deficiency, and have a 95% reduction in fed liver glycogen content. They have mild hypoglycemia but dispose glucose less well in a glucose tolerance test. Fed, LGSKO mice also have a reduced capacity for exhaustive exercise compared with mice carrying floxed alleles, but the difference disappears after an overnight fast. Upon fasting, LGSKO mice reach within 4 h decreased blood glucose levels attained by control floxed mice only after 24 h of food deprivation. The LGSKO mice maintain this low blood glucose for at least 24 h. Basal gluconeogenesis is increased in LGSKO mice, and insulin suppression of endogenous glucose production is impaired as assessed by euglycemic-hyperinsulinemic clamp. This observation correlates with an increase in the liver gluconeogenic enzyme phosphoenolpyruvate carboxykinase expression and activity. This mouse model mimics the pathophysiology of glycogen storage disease 0 patients and highlights the importance of liver glycogen stores in whole body glucose homeostasis.
摄入葡萄糖在体内主要转化为糖原。糖原合成的限速酶是由两个基因编码的糖原合酶,GYS1 在肌肉和其他组织中表达,GYS2 主要在肝脏中表达(肝糖原合酶)。GYS2 缺陷导致遗传性单基因疾病糖原贮积症 0。我们使用 Lox-P/Cre 技术,在肝脏中特异性敲除 Gys2 基因(肝糖原合酶敲除(LGSKO)小鼠)生成了小鼠。带有 floxed Gys2 的条件性小鼠与在白蛋白启动子下表达 Cre 重组酶的小鼠交配。所得 LGSKO 小鼠具有活力,表现出肝糖原合酶缺乏,并表现出喂养时肝糖原含量降低 95%。它们有轻度低血糖症,但在葡萄糖耐量试验中葡萄糖的处理能力较差。在喂养时,LGSKO 小鼠与携带 floxed 等位基因的小鼠相比,进行剧烈运动的能力降低,但在禁食一夜后这种差异消失。禁食后,LGSKO 小鼠在 4 小时内达到与对照 floxed 小鼠相同的低血糖水平,而对照 floxed 小鼠在禁食 24 小时后才达到这种水平。LGSKO 小鼠至少在 24 小时内保持这种低血糖水平。LGSKO 小鼠的基础糖异生增加,并且通过正葡萄糖-高胰岛素钳夹评估,胰岛素对内源性葡萄糖产生的抑制受损。这一观察结果与肝糖异生酶磷酸烯醇丙酮酸羧激酶表达和活性的增加相关。这种小鼠模型模拟了糖原贮积症 0 患者的病理生理学,并强调了肝脏糖原储存对全身葡萄糖稳态的重要性。